FDA clears blood test to aid evaluation for Alzheimer's disease

The U.S. Food and Drug Administration (FDA) has cleared an innovative blood test for marketing. The test's underlying technology was invented at Washington University School of Medicine in St. Louis for the early diagnosis of Alzheimer's disease. The test, known as PrecivityAD2, was developed and validated by C2N Diagnostics, a WashU startup.

Read it at Medical Xpress ↗

← Front page